Long-term alcohol use can lead to fatty liver disease, metabolic syndrome, and systemic inflammation, conditions that complicate treatment.37, 38, 39 GLP-1R agonists and tirzepatide have shown effects on metabolic liver disease and inflammatory processes.58, 59, 60, 61 Given the notable reduction in body weight we observed during the repeated treatment (Exp 11), we additionally explored whether tirzepatide might also affect metabolic and inflammatory parameters in alcohol-consuming animals. This evidence concerns the gene GLP1R and fatty liver disease.